The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2015

Filed:

Jun. 14, 2007
Applicants:

Peter S. Linsley, Encinitas, CA (US);

Janell Schelter, Bellevue, WA (US);

Julja Burchard, San Francisco, CA (US);

Lee Lim, San Francisco, CA (US);

Miho Kibukawa, Bothell, WA (US);

Inventors:

Peter S. Linsley, Encinitas, CA (US);

Janell Schelter, Bellevue, WA (US);

Julja Burchard, San Francisco, CA (US);

Lee Lim, San Francisco, CA (US);

Miho Kibukawa, Bothell, WA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C12N 15/11 (2006.01);
U.S. Cl.
CPC ...
C12N 15/111 (2013.01); C12N 2310/14 (2013.01); C12N 2320/12 (2013.01); C12N 2330/10 (2013.01); C12N 2330/31 (2013.01);
Abstract

In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5' end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5″end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8. In some embodiments, the method comprises introducing at least one iRNA that inhibits the expression of at least one miR-16 responsive gene selected from TABLE 5 into the mammalian cell.


Find Patent Forward Citations

Loading…